|
För ytterligare information, v. v kontakta:
Teva:
Dan Suesskind
Chief Financial Officer
Teva Pharmaceutical Industries Ltd.
+ 972 2 589 28 40 |
Active Biotech:
Sven Andréasson
Verkställande direktör
046 19 20 49 |
|
George Barrett
President and CEO Teva North America +1 215 591 30 30 |
Tomas Leanderson
Chief Scientific Officer
046 19 20 95 |
|
Liraz Kalif / Kevin Mannix Teva Investor Relations +972 3 926 72 81 / +1 215 591 89 12 |
Cecilia Hofvander
Manager Corporate Communication
046 19 11 22 |
ACTIVE BIOTECH OCH TEVA INLEDER REGISTRERINGSGRUNDANDE FAS III-PRÖVNINGAR AV SITT ORALA MS-PREPARAT LAQUINIMOD
| Source: Active Biotech
Attachments
